1
|
Lim C, Lee S, Shin Y, Cho S, Park C, Shin Y, Song EC, Kim WK, Ham C, Kim SB, Kwon YS, Oh KT. Development and application of novel peptide-formulated nanoparticles for treatment of atopic dermatitis. J Mater Chem B 2023; 11:10131-10146. [PMID: 37830254 DOI: 10.1039/d3tb01202f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2023]
Abstract
Atopic dermatitis is a chronic inflammatory skin condition that is characterized by skin inflammation, itching, and redness. Although various treatments can alleviate symptoms, they often come with side effects, highlighting the need for new treatments. Here, we discovered a new peptide-based therapy using the intra-dermal delivery technology (IDDT) platform developed by Remedi Co., Ltd (REMEDI). The platform screens and identifies peptides derived from proteins in the human body that possess cell-penetrating peptide (CPP) properties. We screened over 1000-peptides and identified several derived from the Speckled protein (SP) family that have excellent CPP properties and have anti-inflammatory effects. We assessed these peptides for their potential as a treatment for atopic dermatitis. Among them, the RMSP1 peptide showed the most potent anti-inflammatory effects by inhibiting the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and signal transducer and activator of transcription 3 (STAT3) signaling pathways while possessing CPP properties. To further improve efficacy and stability, we developed a palmitoylated version called Pal-RMSP1. Formulation studies using liposomes (Pal-RMSP1 LP) and micelles (Pal-RMSP1 DP) demonstrated improved anti-inflammatory effects in vitro and enhanced therapeutic effects in vivo. Our study indicates that nano-formulated Pal-RMSP1 could have the potential to become a new treatment option for atopic dermatitis.
Collapse
Affiliation(s)
- Chaemin Lim
- College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.
- College of Pharmacy, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam-si, 13488 Gyeonggi-do, Republic of Korea
| | - Subin Lee
- College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.
- Department of Global Innovative Drugs, The Graduate School of Chung-Ang University, Seoul 06974, Republic of Korea
| | - Yuseon Shin
- College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.
- Department of Global Innovative Drugs, The Graduate School of Chung-Ang University, Seoul 06974, Republic of Korea
| | - Seongmin Cho
- Remedi Co., Ltd. Research Center, Songdo 21990, Republic of Korea
| | - Chanho Park
- Remedi Co., Ltd. Research Center, Songdo 21990, Republic of Korea
| | - Yungyeong Shin
- Remedi Co., Ltd. Research Center, Songdo 21990, Republic of Korea
| | - Ee Chan Song
- Remedi Co., Ltd. Research Center, Songdo 21990, Republic of Korea
| | - Wan Ki Kim
- Remedi Co., Ltd. Research Center, Songdo 21990, Republic of Korea
| | - Cheolmin Ham
- Rare Isotope Science Project, Institute for Basic Science, Daejeon 34000, Republic of Korea
| | - Sang Bum Kim
- College of Pharmacy, Sahmyook University, Seoul 01795, Republic of Korea
| | - Yong-Su Kwon
- Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA
| | - Kyung Taek Oh
- College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.
- Department of Global Innovative Drugs, The Graduate School of Chung-Ang University, Seoul 06974, Republic of Korea
| |
Collapse
|
2
|
Song EC, Park C, Shin Y, Kim WK, Kim SB, Cho S. Neurog1-Derived Peptides RMNE1 and DualPep-Shine Penetrate the Skin and Inhibit Melanin Synthesis by Regulating MITF Transcription. Int J Mol Sci 2023; 24:ijms24076158. [PMID: 37047130 PMCID: PMC10094136 DOI: 10.3390/ijms24076158] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 03/22/2023] [Accepted: 03/23/2023] [Indexed: 04/14/2023] Open
Abstract
Anti-pigmentation peptides have been developed as alternative skin-lightening agents to replace conventional chemicals that have adverse effects on the skin. However, the maximum size of these peptides is often limited by their low skin and cell penetration. To address this issue, we used our intra-dermal delivery technology (IDDT) platform to identify peptides with hypo-pigmenting and high cell-penetrating activity. Using our cell-penetrating peptides (CPPs) from the IDDT platform, we identified RMNE1 and its derivative RMNE3, "DualPep-Shine", which showed levels of α-Melanocyte stimulating hormone (α-MSH)-induced melanin inhibition comparable to the conventional tyrosinase inhibitor, Kojic acid. In addition, DualPep-Shine was delivered into the nucleus and regulated the gene expression levels of melanogenic enzymes by inhibiting the promoter activity of microphthalmia-associated transcription factor-M (MITF-M). Using a 3D human skin model, we found that DualPep-Shine penetrated the lower region of the epidermis and reduced the melanin content in a dose-dependent manner. Furthermore, DualPep-Shine showed high safety with little immunogenicity, indicating its potential as a novel cosmeceutical ingredient and anti-pigmentation therapeutic agent.
Collapse
Affiliation(s)
- Ee Chan Song
- Remedi Co., Ltd., Research Center, Incheon 21990, Republic of Korea
| | - Chanho Park
- Remedi Co., Ltd., Research Center, Incheon 21990, Republic of Korea
| | - Yungyeong Shin
- Remedi Co., Ltd., Research Center, Incheon 21990, Republic of Korea
| | - Wan Ki Kim
- Remedi Co., Ltd., Research Center, Incheon 21990, Republic of Korea
| | - Sang Bum Kim
- College of Pharmacy, Sahmyook University, Seoul 01795, Republic of Korea
| | - Seongmin Cho
- Remedi Co., Ltd., Research Center, Incheon 21990, Republic of Korea
| |
Collapse
|
3
|
Cho S, Kim SB, Lee Y, Song EC, Kim U, Kim HY, Suh JH, Goughnour PC, Kim Y, Yoon I, Shin NY, Kim D, Kim IK, Kang CY, Jang SY, Kim MH, Kim S. Endogenous TLR2 ligand embedded in the catalytic region of human cysteinyl-tRNA synthetase 1. J Immunother Cancer 2021; 8:jitc-2019-000277. [PMID: 32461342 PMCID: PMC7254149 DOI: 10.1136/jitc-2019-000277] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/24/2020] [Indexed: 12/21/2022] Open
Abstract
Background The generation of antigen-specific cytotoxic T lymphocyte (CTL) responses is required for successful cancer vaccine therapy. In this regard, ligands of Toll-like receptors (TLRs) have been suggested to activate adaptive immune responses by modulating the function of antigen-presenting cells (APCs). Despite their therapeutic potential, the development of TLR ligands for immunotherapy is often hampered due to rapid systemic toxicity. Regarding the safety concerns of currently available TLR ligands, finding a new TLR agonist with potent efficacy and safety is needed. Methods A unique structural domain (UNE-C1) was identified as a novel TLR2/6 in the catalytic region of human cysteinyl-tRNA synthetase 1 (CARS1) using comprehensive approaches, including RNA sequencing, the human embryonic kidney (HEK)-TLR Blue system, pull-down, and ELISA. The potency of its immunoadjuvant properties was analyzed by assessing antigen-specific antibody and CTL responses. In addition, the efficacy of tumor growth inhibition and the presence of the tumor-infiltrating leukocytes were evaluated using E.G7-OVA and TC-1 mouse models. The combined effect of UNE-C1 with an immune checkpoint inhibitor, anti-CTLA-4 antibody, was also evaluated in vivo. The safety of UNE-C1 immunization was determined by monitoring splenomegaly and cytokine production in the blood. Results Here, we report that CARS1 can be secreted from cancer cells to activate immune responses via specific interactions with TLR2/6 of APCs. A unique domain (UNE-C1) inserted into the catalytic region of CARS1 was determined to activate dendritic cells, leading to the stimulation of robust humoral and cellular immune responses in vivo. UNE-C1 also showed synergistic efficacy with cancer antigens and checkpoint inhibitors against different cancer models in vivo. Further, the safety assessment of UNE-C1 showed lower systemic cytokine levels than other known TLR agonists. Conclusions We identified the endogenous TLR2/6 activating domain from human cysteinyl-tRNA synthetase CARS1. This novel TLR2/6 ligand showed potent immune-stimulating activity with little toxicity. Thus, the UNE-C1 domain can be developed as an effective immunoadjuvant with checkpoint inhibitors or cancer antigens to boost antitumor immunity.
Collapse
Affiliation(s)
- Seongmin Cho
- Medicinal Bioconvergence Research Center and College of Pharmacy, Seoul National University, Suwon, South Korea.,Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Pharmacy, Seoul National University, Seoul, South Korea
| | - Sang Bum Kim
- Medicinal Bioconvergence Research Center and College of Pharmacy, Seoul National University, Suwon, South Korea.,Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Pharmacy, Seoul National University, Seoul, South Korea
| | - Youngjin Lee
- Infection and Immunity Research Laboratory, Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea
| | - Ee Chan Song
- Medicinal Bioconvergence Research Center and College of Pharmacy, Seoul National University, Suwon, South Korea.,Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Pharmacy, Seoul National University, Seoul, South Korea
| | - Uijoo Kim
- Medicinal Bioconvergence Research Center and College of Pharmacy, Seoul National University, Suwon, South Korea.,Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Pharmacy, Seoul National University, Seoul, South Korea
| | - Hyeong Yun Kim
- Medicinal Bioconvergence Research Center and College of Pharmacy, Seoul National University, Suwon, South Korea.,Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Pharmacy, Seoul National University, Seoul, South Korea
| | - Ji Hun Suh
- Medicinal Bioconvergence Research Center and College of Pharmacy, Seoul National University, Suwon, South Korea.,Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Pharmacy, Seoul National University, Seoul, South Korea
| | - Peter C Goughnour
- Medicinal Bioconvergence Research Center and College of Pharmacy, Seoul National University, Suwon, South Korea
| | - YounHa Kim
- Medicinal Bioconvergence Research Center and College of Pharmacy, Seoul National University, Suwon, South Korea
| | - Ina Yoon
- Medicinal Bioconvergence Research Center and College of Pharmacy, Seoul National University, Suwon, South Korea
| | - Na Young Shin
- Medicinal Bioconvergence Research Center and College of Pharmacy, Seoul National University, Suwon, South Korea
| | - Doyeun Kim
- Medicinal Bioconvergence Research Center and College of Pharmacy, Seoul National University, Suwon, South Korea
| | - Il-Kyu Kim
- Laboratory of Immunology, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, South Korea
| | - Chang-Yuil Kang
- Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Pharmacy, Seoul National University, Seoul, South Korea.,Laboratory of Immunology, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, South Korea
| | - Song Yee Jang
- Infection and Immunity Research Laboratory, Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea
| | - Myung Hee Kim
- Infection and Immunity Research Laboratory, Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea
| | - Sunghoon Kim
- Medicinal Bioconvergence Research Center and College of Pharmacy, Seoul National University, Suwon, South Korea .,Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Pharmacy, Seoul National University, Seoul, South Korea
| |
Collapse
|